Merck's Keytruda First-Line Improves Esophageal Cancer Survival
Regardless Of Histology, When Combined With Chemotherapy
Merck & Co is working hard to extend the indications for Keytruda, and reports the checkpoint inhibitor significantly improves overall survival and PFS when combined with chemotherapy in the first-line treatment of metastatic esophageal cancer.
You may also be interested in...
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.